News

Public · Published

TWST: FY26 delivered 22% revenue growth and positive Q4 adjusted EBITDA, backing a >20% FY27 growth outlook

Twist Bioscience reported that FY26 revenue grew 22% and adjusted EBITDA, a measure of operating earnings, turned positive in the fourth quarter. Its FY27 outlook calls for more than 20% growth, with AI discovery, next-generation sequencing and capacity expansion identified as drivers.

Published:

Updated:

What happened

Twist Bioscience reported that FY26 revenue grew 22% and adjusted EBITDA, a measure of operating earnings, turned positive in the fourth quarter. Its FY27 outlook calls for more than 20% growth, with AI discovery, next-generation sequencing and capacity expansion identified as drivers.

Confirmed

Global impact / market context

The outlook points to continued sales growth, while expanding capacity and ramping operations require investment and may limit improvement in profit per sale. If growth materializes, added revenue could help cover those costs; if costs rise faster, earnings progress may lag sales.

Analyst inference

The supplied article gives a positive growth outlook but also flags investment and ramp costs as possible constraints on margin expansion, meaning the share of revenue left after costs. It provides no valuation, cash-flow details or market reaction to weigh the outlook further.

Analyst inference

What to watch

  1. Check future revenue reports against the FY27 outlook of more than 20% growth, and look for updates on AI discovery and next-generation sequencing contributions. Analyst inference
  2. Watch for company updates on capacity expansion and planned investment, which could show whether added operating capacity is proceeding alongside expected demand. Analyst inference
  3. Track whether adjusted EBITDA remains positive and whether ramp costs temper margin expansion, since those outcomes indicate how growth translates into operating earnings. Analyst inference

Evidence

  • Original source link unavailable